Treatment With a Monocyte-Targeting Agent for Pancreatic Cancer

News
Article

Andrea Wang-Gillam, MD, PhD, discusses a trial looking at PF-04136309, an investigational chemokine receptor antagonist, in combination with FOLFIRINOX for the treatment of locally advanced pancreatic cancer.

Andrea Wang-Gillam, MD, PhD, assistant professor, Department of Medicine, Oncology Division, Washington University School of Medicine in St. Louis, discusses a trial looking at PF-04136309, an investigational chemokine receptor antagonist, in combination with FOLFIRINOX for the treatment of locally advanced pancreatic cancer.

More on this trial > >

<<<

Back to the Gastrointestinal Cancers Symposium conference page

Recent Videos
Related Content
T-DM1 Shows Tolerability in HER2+ Biliary Tract Adenocarcinoma

T-DM1 Shows Tolerability in HER2+ Biliary Tract Adenocarcinoma

Ariana Pelosci
February 3rd 2025
Article

T-DM1 was tolerable in HER2-positive biliary tract adenocarcinoma but did not significantly improve progression-free survival.

Read More

Bevacizumab Benefits in CRC Persist for Two Years After Initiation

Bevacizumab Benefits in CRC Persist for Two Years After Initiation

Darlene Dobkowski, MA
February 1st 2025
Article

Bevacizumab's survival benefits in CRC patients persist for about 2 years after starting treatment.

Read More

Poor Outcomes Seen in BRAF V600E-Mutant mCRC With Systemic Therapy

Poor Outcomes Seen in BRAF V600E-Mutant mCRC With Systemic Therapy

Russ Conroy
January 31st 2025
Article

Patients with BRAF V600E-mutant metastatic colorectal cancer experienced poor clinical outcomes with systemic therapy, according to real-world data.

Read More

Watch and Wait Post-TNT Safe with Similar Outcomes to TME in Rectal Cancer

Watch and Wait Post-TNT Safe with Similar Outcomes to TME in Rectal Cancer

Roman Fabbricatore
January 31st 2025
Article

A "watch and wait" strategy after total neoadjuvant therapy showed similar outcomes and safety to total mesorectal in stage II/III rectal cancer.

Read More

Early Palliative Care Improves EOL Comfort in Colorectal Cancer

Early Palliative Care Improves EOL Comfort in Colorectal Cancer

Roman Fabbricatore
January 30th 2025
Article

Early palliative care reduces invasive interventions and enhances comfort at EOL for CRC patients, according to real-world study results.

Read More

Oral Paclitaxel Outperforms IV in OS for Advanced Gastric Cancer

Oral Paclitaxel Outperforms IV in OS for Advanced Gastric Cancer

Ryan Scott
January 28th 2025
Article

Oral paclitaxel matched IV in progression-free survival but outperformed it in overall survival for second-line advanced gastric cancer.

Read More